Impact of the 2021 ESC Prevention Guideline’s stepwise approach for cardiovascular risk factor treatment in patients with established ASCVD
Joris Holtrop,Deepak L Bhatt,Kausik K Ray,François Mach,Yvo M Smulders,David Carballo,Philippe Gabriel Steg,Frank L J Visseren,Jannick A N Dorresteijn
DOI: https://doi.org/10.1093/eurjpc/zwae038
IF: 8.526
2024-02-07
European Journal of Preventive Cardiology
Abstract:Abstract Background and Aims To evaluate the stepwise-approach for cardiovascular (CV) risk factor treatment as outlined by the ESC 2021 Guidelines on CV Disease (CVD) Prevention in patients with established atherosclerotic CVD (ASCVD) Methods In patients with ASCVD, included in UCC-SMART (n = 8,730) and European parts of the REACH registry (n = 18,364), the 10-year CV risk was estimated using SMART2. Treatment effects were derived from meta-analyses and trials. Step 1 recommendations were LDL-cholesterol (LDLc) < 1.8 mmol/L, systolic blood pressure (SBP) < 140 mmHg, using any antithrombotic medication, sodium glucose co-transporter 2 (SGLT2) inhibition, and smoking cessation. Step 2 recommendations were LDLc <1.4 mmol/L, SBP <130 mmHg, dual pathway inhibition (DPI, aspirin plus low-dose rivaroxaban), colchicine, glucagon-like peptide (GLP)-1 receptor agonists, and eicosapentaenoic acid. Step 2 was modelled accounting for Step 1 non-attainment. Results With current treatment residual CV risk was 22%, 32%, and 60% in the low, moderate, and pooled (very) high European risk regions, respectively. Step 2 could prevent up to 198, 223, 245 events per 1000 patients treated, respectively. Intensified LDLc-reduction, colchicine, and DPI could be applied to most patients, preventing up to 57, 74, and 59 events per 1000 patients treated, respectively. Following Step 2 the number of patients with a CV risk of <10% could increase from 20%, 6.4%, and 0.5%, following Step 1, to 63%, 48%, and 12%, in the respective risk regions. Conclusions With current treatment residual CV risk in patients with ASCVD remains high across all European risk regions. The intensified Step 2 treatment options result in marked further reduction of residual CV risk in patients with established ASCVD.
cardiac & cardiovascular systems